Compare NHTC & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NHTC | CGTX |
|---|---|---|
| Founded | 1988 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 94.5M |
| IPO Year | 1999 | 2021 |
| Metric | NHTC | CGTX |
|---|---|---|
| Price | $3.07 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 24.7K | ★ 637.8K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | ★ 12.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,776,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.40 | $0.22 |
| 52 Week High | $5.48 | $3.83 |
| Indicator | NHTC | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.95 | 44.15 |
| Support Level | $2.95 | $1.00 |
| Resistance Level | $3.38 | $1.19 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 21.05 | 34.29 |
Natural Health Trends Corp is an international direct-selling and e-commerce company. It offers a line of products such as Wellness, Herbal, Beauty, Lifestyle, and Home. Wellness products include targeted nutrition for joint health, antioxidant support, digestive health, heart health, and vision health. Herbal products include anti-aging and hydrating cleansers, creams, lotions, serums, and toners. Lifestyle products improve the overall quality of life and support active, physical, and healthy lifestyles. Home products are designed to create a clean and natural living environment for the home. It generates a majority of its revenue from Hong Kong and the rest from China, Taiwan, Japan, the United States, and other regions.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.